



## Taking Neo-Antigen Vaccines Forward

Guest Editor:

**Prof. Dr. Karim Vermaelen**

Department of Pulmonary  
Medicine, Ghent University, 9000  
Ghent, Belgium

Deadline for manuscript  
submissions:

**closed (31 October 2022)**

### Message from the Guest Editor

Dear Colleagues,

Inducing effective adaptive immune responses against neoantigens has become an intensively explored way to fight cancer. The idea is to enrich for highly tumor-specific T-cell responses, turning “cold” into “hot” tumors thus potentiating the effects of existing immunotherapies such as immune checkpoint blockade. This approach drives a revival of vaccines in oncology.

This Special Issue aims to provide the reader with the State-of-the-Art in neoantigen vaccine development and give a glimpse of its future. Papers pertaining to genomic and proteomic neoantigen discovery pipelines, clinical applications and results so far, regulatory aspects of neoantigen-targeted therapies and other related topics are welcome. In addition to the field of cancer, papers dealing with the use of microbial-derived xeno-epitopes for vaccination purposes will be considered as well.

Prof. Dr. Karim Vermaelen

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)